Skip to main content

Peer Review reports

From: Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer

Original Submission
17 Nov 2021 Submitted Original manuscript
21 Jan 2022 Reviewed Reviewer Report
27 Jan 2022 Reviewed Reviewer Report
4 Feb 2022 Reviewed Reviewer Report
31 Mar 2022 Author responded Author comments - Linlin Wang
Resubmission - Version 2
31 Mar 2022 Submitted Manuscript version 2
12 Apr 2022 Reviewed Reviewer Report
25 Apr 2022 Reviewed Reviewer Report
3 May 2022 Reviewed Reviewer Report
15 May 2022 Author responded Author comments - Linlin Wang
Resubmission - Version 3
15 May 2022 Submitted Manuscript version 3
9 Jun 2022 Author responded Author comments - Linlin Wang
Resubmission - Version 4
9 Jun 2022 Submitted Manuscript version 4
13 Jun 2022 Reviewed Reviewer Report
7 Jul 2022 Author responded Author comments - Linlin Wang
Resubmission - Version 5
7 Jul 2022 Submitted Manuscript version 5
9 Jul 2022 Author responded Author comments - Linlin Wang
Resubmission - Version 6
9 Jul 2022 Submitted Manuscript version 6
11 Jul 2022 Author responded Author comments - Linlin Wang
Resubmission - Version 7
11 Jul 2022 Submitted Manuscript version 7
Publishing
19 Jul 2022 Editorially accepted
29 Jul 2022 Article published 10.1186/s12885-022-09918-1

You can find further information about peer review here.

Back to article page